B-020 Atellica Solution® 分析仪和 CI® 分析仪检测 T4L、β-HCG 总量和 PSA 总量的方法相互比较研究

IF 7.1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY
M Ruiz-Alvarez, S Lapeña-Garcia, S Garcia-Valdecasas, T Costales-Lucia, J De La Rubia-Maestu, M Barrionuevo-Gonzalez
{"title":"B-020 Atellica Solution® 分析仪和 CI® 分析仪检测 T4L、β-HCG 总量和 PSA 总量的方法相互比较研究","authors":"M Ruiz-Alvarez, S Lapeña-Garcia, S Garcia-Valdecasas, T Costales-Lucia, J De La Rubia-Maestu, M Barrionuevo-Gonzalez","doi":"10.1093/clinchem/hvae106.384","DOIUrl":null,"url":null,"abstract":"Background Method intercomparison is an essential requirement in Clinical Laboratories before changing a method or instrument to verify the interchangeability of results. After validating a new Siemens device, the CI®, we conducted an intercomparison study with the Atellica Solution® for T4 free (T4L), β-HCG total, and PSA total assays. Objectives To check the interchangeability of results between the methods of T4L, β-HCG total, and PSA total, as determined on the Atellica Solution® and CI® analyzers, to evaluate the behavior of both equipment in our laboratory as a single virtual team. Methods A total of 120 serum samples from patients with T4L values between 0.41 and 7.5 ng/dL, β-HCG total between 0.5 and 1000 mIU/mL, and PSA total between 0.01 and 78.4 ng/mL were processed on both analyzers. Passing-Bablok regression, Bland-Altman analysis, and Pearson correlation coefficient were used to evaluate the sample size. Results are expressed with a 95% confidence interval. The intercomparison study was conducted using Method Validator Version 1.19. Results See table Conclusions After evaluating the results, we conclude that the Atellica Solution® and CI® analyzers behave as a single virtual team for the T4L, β-HCG total, and PSA total assays. Although there are systematic errors, they do not exceed the quality specifications established in our laboratory, based on the Total Error allowable according to Biological Variability.","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":"76 1","pages":""},"PeriodicalIF":7.1000,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"B-020 Study of Method Intercomparison between Atellica Solution® and CI® Analyzers for T4L, β-HCG Total, and PSA Total\",\"authors\":\"M Ruiz-Alvarez, S Lapeña-Garcia, S Garcia-Valdecasas, T Costales-Lucia, J De La Rubia-Maestu, M Barrionuevo-Gonzalez\",\"doi\":\"10.1093/clinchem/hvae106.384\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background Method intercomparison is an essential requirement in Clinical Laboratories before changing a method or instrument to verify the interchangeability of results. After validating a new Siemens device, the CI®, we conducted an intercomparison study with the Atellica Solution® for T4 free (T4L), β-HCG total, and PSA total assays. Objectives To check the interchangeability of results between the methods of T4L, β-HCG total, and PSA total, as determined on the Atellica Solution® and CI® analyzers, to evaluate the behavior of both equipment in our laboratory as a single virtual team. Methods A total of 120 serum samples from patients with T4L values between 0.41 and 7.5 ng/dL, β-HCG total between 0.5 and 1000 mIU/mL, and PSA total between 0.01 and 78.4 ng/mL were processed on both analyzers. Passing-Bablok regression, Bland-Altman analysis, and Pearson correlation coefficient were used to evaluate the sample size. Results are expressed with a 95% confidence interval. The intercomparison study was conducted using Method Validator Version 1.19. Results See table Conclusions After evaluating the results, we conclude that the Atellica Solution® and CI® analyzers behave as a single virtual team for the T4L, β-HCG total, and PSA total assays. Although there are systematic errors, they do not exceed the quality specifications established in our laboratory, based on the Total Error allowable according to Biological Variability.\",\"PeriodicalId\":10690,\"journal\":{\"name\":\"Clinical chemistry\",\"volume\":\"76 1\",\"pages\":\"\"},\"PeriodicalIF\":7.1000,\"publicationDate\":\"2024-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/clinchem/hvae106.384\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/clinchem/hvae106.384","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景方法比对是临床实验室在更换方法或仪器以验证结果互换性之前的一项基本要求。在验证了西门子的新设备 CI® 之后,我们又与 Atellica Solution® 进行了游离 T4 (T4L)、β-HCG 总量和 PSA 总量测定方法的比对研究。目的 检查 Atellica Solution® 和 CI® 分析仪测定 T4L、β-HCG 总量和 PSA 总量的方法之间结果的互换性,以评估这两种设备在我们实验室作为一个虚拟团队的行为。方法 在两种分析仪上共处理了 120 份患者血清样本,这些样本的 T4L 值在 0.41 至 7.5 ng/dL 之间,β-HCG 总量在 0.5 至 1000 mIU/mL 之间,PSA 总量在 0.01 至 78.4 ng/mL 之间。使用 Passing-Bablok 回归、Bland-Altman 分析和 Pearson 相关系数评估样本量。结果以 95% 的置信区间表示。比对研究使用方法验证器 1.19 版进行。结果 见表 结论 评估结果后,我们得出结论:Atellica Solution® 和 CI® 分析仪在 T4L、β-HCG 总量和 PSA 总量检测中表现得像一个虚拟团队。虽然存在系统误差,但根据生物变异性允许的总误差,这些误差并未超出我们实验室制定的质量标准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
B-020 Study of Method Intercomparison between Atellica Solution® and CI® Analyzers for T4L, β-HCG Total, and PSA Total
Background Method intercomparison is an essential requirement in Clinical Laboratories before changing a method or instrument to verify the interchangeability of results. After validating a new Siemens device, the CI®, we conducted an intercomparison study with the Atellica Solution® for T4 free (T4L), β-HCG total, and PSA total assays. Objectives To check the interchangeability of results between the methods of T4L, β-HCG total, and PSA total, as determined on the Atellica Solution® and CI® analyzers, to evaluate the behavior of both equipment in our laboratory as a single virtual team. Methods A total of 120 serum samples from patients with T4L values between 0.41 and 7.5 ng/dL, β-HCG total between 0.5 and 1000 mIU/mL, and PSA total between 0.01 and 78.4 ng/mL were processed on both analyzers. Passing-Bablok regression, Bland-Altman analysis, and Pearson correlation coefficient were used to evaluate the sample size. Results are expressed with a 95% confidence interval. The intercomparison study was conducted using Method Validator Version 1.19. Results See table Conclusions After evaluating the results, we conclude that the Atellica Solution® and CI® analyzers behave as a single virtual team for the T4L, β-HCG total, and PSA total assays. Although there are systematic errors, they do not exceed the quality specifications established in our laboratory, based on the Total Error allowable according to Biological Variability.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical chemistry
Clinical chemistry 医学-医学实验技术
CiteScore
11.30
自引率
4.30%
发文量
212
审稿时长
1.7 months
期刊介绍: Clinical Chemistry is a peer-reviewed scientific journal that is the premier publication for the science and practice of clinical laboratory medicine. It was established in 1955 and is associated with the Association for Diagnostics & Laboratory Medicine (ADLM). The journal focuses on laboratory diagnosis and management of patients, and has expanded to include other clinical laboratory disciplines such as genomics, hematology, microbiology, and toxicology. It also publishes articles relevant to clinical specialties including cardiology, endocrinology, gastroenterology, genetics, immunology, infectious diseases, maternal-fetal medicine, neurology, nutrition, oncology, and pediatrics. In addition to original research, editorials, and reviews, Clinical Chemistry features recurring sections such as clinical case studies, perspectives, podcasts, and Q&A articles. It has the highest impact factor among journals of clinical chemistry, laboratory medicine, pathology, analytical chemistry, transfusion medicine, and clinical microbiology. The journal is indexed in databases such as MEDLINE and Web of Science.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信